OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Substance Abuse Treatment is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)

Article	Citations
C2: editorial board	116
JSAT call for papers for special issue: Stimulant use disorder	98
Barriers to accessing treatment for substance use after inpatient managed withdrawal (Detox): A qualitative study	83
The impact of military sexual trauma and gender on receipt of evidence-based medication treatment among veterans with opioid use disorder	81
Augmenting substance use treatment in the drug court: A pilot randomized trial of peer recovery support	71
Hepatitis C treatment outcomes among patients treated in co-located primary care and addiction treatment settings	63
Substance use disorders among older populations: What role do race and ethnicity play in treatment and completion?	56
A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail	55
Community perspectives on supervised consumption sites: Insights from four U.S. counties deeply affected by opioids	50
A qualitative study of service engagement and unmet needs among unstably housed people who inject drugs in Massachusetts	49
Integrating substance use care into primary care for adolescents and young adults: Lessons learned	49
Perspectives on electronic portal use among patients treated with medications for opioid use disorder in primary care	48
The new services that opioid treatment programs have adopted in response to COVID-19	47
C2: editorial board	47
Sex-based differences in psychiatric symptoms and opioid abstinence during buprenorphine/naloxone treatment in adolescents with opioid use disorders	45
Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data	44
Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up	42
Views of barriers and facilitators to continuing methadone treatment upon release from jail among people receiving patient navigation services	42
Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail	42
Education and careers were our way out	39
Experiences of stigma among individuals in recovery from opioid use disorder in a rural setting: A qualitative analysis	39
Serial mediation analysis of treatment-specific processes in two contrasting alcohol treatments	38
Suicide safer care in behavioral health settings: A comparative analysis of perceptions, training completion, and practice between mental health and substance use disorder treatment providers	38
C2: editorial board	36
Al-Anon Intensive Referral (AIR): A qualitative formative evaluation for implementation	33

Massachusetts Justice Community Opioid Innovation Network (MassJCOIN)	33
What is the relapse risk during treatment? Survivor analysis of single and multiple relapse events in inpatients with alcohol use disorder as part of an observational study	32
Use of non–prescribed buprenorphine in the criminal justice system: Perspectives of individuals recently released from incarceration	31
A randomized clinical trial evaluating the impact of counselor training and patient feedback on substance use disorder patients' sexual risk behavior	30
What is success in treatment for opioid use disorder? Perspectives of physicians and patients in primary care settings	30
Incarceration and compulsory rehabilitation impede use of medication for opioid use disorder and HIV care engagement in Vietnam	30
Emergency department interventions for opioid use disorder: A synthesis of emerging models	30
Association between industry sponsorship and author conflicts of interest with outcomes of systematic reviews and meta-analyses of interventions for opioid use disorder	30
Suboptimal nonmedical qualities of primary care linked with care avoidance among people who use drugs in a Canadian setting amid an integrated health care reform	29
Stepped-wedge randomized controlled trial of a novel opioid court to improve identification of need and linkage to medications for opioid use disorder treatment for court-involved adults	28
Can nicotine replacement therapy be personalized? A statistical learning analysis	28
Targeting women veteran's stress-induced drinking with cognitive reappraisal: Mechanisms and moderators of change	28
Facing the future of substance use disorders treatment in Vietnam – A case study for international development and cooperation	28
Using machine learning to identify predictors of imminent drinking and create tailored messages for at-risk drinkers experiencing homelessness	27
Adapting methadone inductions to the fentanyl era	26
Facilitating engagement of persons with opioid use disorder in treatment for hepatitis C virus infection via telemedicine: Stories of onsite case managers	26
Associations of retention on buprenorphine for opioid use disorder with patient characteristics and models of care in the primary care setting	25
Tobacco smoking and nicotine dependence among patients with respiratory diseases in Vietnam: Status and correlated factors	25
The impact of social network dynamics on engagement in drug use reduction programs among men and women who use drugs	24
Connecting and disconnecting: Experiences of people with opioid use disorder in intensive outpatient treatment	24
Improving geographic access to methadone clinics	24
A randomized clinical trial of strengths-based case management to link emergency department patients to opioid use disorder treatment	24
Addressing adolescent substance use in an urban pediatric federally qualified health center	24
Using machine learning to examine predictors of treatment goal change among individuals seeking treatment for alcohol use disorder	24
Mobile-based brief interventions targeting cannabis-impaired driving among youth: A Delphi study	23
Drug court utilization of medications for opioid use disorder in high opioid mortality communities	23
National trends in substance use treatment admissions for opioid use disorder among adults experiencing homelessness	23
The impact of COVID-19 on substance use disorder treatment in California: Service providers' perspectives	23
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)	23
Frequency and recency of non-medical opioid use and death due to overdose or suicide among individuals assessed for risky substance use: A national registry study in Sweden	23
Development and validation of a claim-based provider-level measurement of use of medications to treat opioid use disorder	23
C2: editorial board	22
Latent class analysis of self-reported substance use during incarceration: Gender differences and associations with emotional distress and aggressiveness	22
Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): A national qualitative study	22
An exploration of thriving over time in recovery	22
Engagement patterns with a digital therapeutic for substance use disorders: Correlations with abstinence outcomes	21
Adapting and scaling a single site DEA X-waiver training program to a statewide initiative: Implementing GetWaiveredTX	21
Knowledge, attitudes, and behaviors related to the fentanyl-adulterated drug supply among people who use drugs in Oregon	20
Recovering from substance use disorders during the early months of the COVID-19 pandemic: A mixed-methods longitudinal study of women in Kansas City	20
The impact of COVID-19 on health care professionals who are exposed to drug-related deaths while supporting clients experiencing addiction	20
Implications of posttraumatic growth for the treatment of comorbid substance abuse among survivors of traumatic experiences	20
Scoping review of interventions to link individuals to substance use services at discharge from jail	20
Where did the specialty behavioral health workforce grow between 2011 and 2019? Evidence from census data	19
Emotion dysregulation and hazardous drinking in relation to suicidal ideation among Spanish-speaking Latinx daily-smokers	19
Beyond harm-producing versus harm-reducing: A qualitative meta-synthesis of people who use drugs' perspectives of and experiences with the extramedical use and diversion of buprenorphine	19
SMART Recovery International and COVID-19: Expanding the reach of mutual support through online groups	19
Recidivism prevention for impaired driving: Longitudinal 5-year outcomes from Quebec's severity-based intervention assignment program	19
Corrigendum to “Feasibility and acceptability of mindful recovery opioid use care continuum (M-ROCC): A concurrent mixed methods study” [Journal of Substance Abuse Treatment 130 (2021) 108415]	19
C2: editorial board	19
Racial disparities in linkage to care among patients with substance use disorders	19

Increased utilization of buprenorphine and methadone in 2018 compared to 2015 among Seattle-area persons who inject drugs	19
Digital delivery of a contingency management intervention for substance use disorder: A feasibility study with DynamiCare Health	19
Contingency management for treatment attendance: A meta-analysis	19
Implementation of buprenorphine initiation and warm handoff protocols in emergency departments: A qualitative study of Pennsylvania hospitals	19
Patterns of enrollment in a New Orleans women's substance use rehabilitation center	18
C2: editorial board	18
Associations between patient experience and clinical outcomes in substance use disorder clinics: Findings from the veterans outcomes assessment survey	18
A pilot randomized clinical trial of mindfulness-oriented recovery enhancement as an adjunct to methadone treatment for people with opioid use disorder and chronic pain: Impact on illicit drug use, he	18
Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study	18
Associations between prescription and illicit stimulant and opioid use in the United States, 2015–2020	18
TOC (update)	18
Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19	17
Alcohol and drug use among bartenders: An at risk population?	17
Cognitive insight, medication adherence and methamphetamine cessation in people enrolled in a pharmacotherapy trial for methamphetamine use	17
Mobile methadone medication units: A brief history, scoping review and research opportunity	17
C2: editorial board	17
Developing a cascade of care for opioid use disorder among individuals in jail	17
Differential impacts of COVID-19 across racial-ethnic identities in persons with opioid use disorder	17
Predictive validity of the New York State Level of Care for Alcohol and Drug Treatment Referral (LOCADTR) for continuous engagement in treatment among individuals recommended for outpatient care	16
Comparison of self-reported substance use with biological testing among treatment-seeking patients with opioid use disorder	16
Mobile low-threshold buprenorphine integrated with infectious disease services	16
Associations between relationship quality and treatment-related stress among couples receiving methadone for opioid use disorder	16
Value of family involvement in substance use disorder treatment: Aligning clinical and financing priorities	16
TOC (update)	16
Follow-up after ED visits for opioid use disorder: Do they reduce future overdoses?	16
The short-term effectiveness of real-time video counselling on smoking cessation among residents in rural and remote areas: An interim analysis of a randomised trial	15
Consumer access to buprenorphine and methadone in certified community behavioral health centers: A secret shopper study	15
Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder	15
C2: editorial board	15
Alcohol use disorder and treatment receipt among individuals aged 50 years and older: Other substance use and psychiatric correlates	15
TOC (update)	15
Prescribing buprenorphine for opioid use disorder in primary care: A survey of French general practitioners in the Sentinelles network	15
Client attitudes toward virtual treatment court	15
How emergency department visits for substance use disorders have evolved during the early COVID-19 pandemic	15
Qualitative characterizations of misinformed disclosure reactions to medications for opioid use disorders and their consequences	15
Treatment access for opioid use disorder in pregnancy among rural and American Indian communities	15
Patient-centered primary care and receipt of evidence-based alcohol-related care in the national Veterans Health Administration	15
The effect of nicotine dependence and withdrawal symptoms on use of nicotine replacement therapy: Secondary analysis of a randomized controlled trial in primary care	15
Reducing Opioid Mortality in Illinois (ROMI): A case management/peer recovery coaching critical time intervention clinical trial protocol	15
Introduction to a Special Issue: Care and treatment for substance use disorders: Studies from around the world	15
The role of recovery housing during outpatient substance use treatment	15
Parental status and characteristics of women in substance use treatment services: Analysis of electronic patient records	15